Developing a new treatment for glioblastoma using a virus and NOTCH blocking strategy
Next Gen Virotherapy for GBM
This study is exploring a new way to treat glioblastoma, an aggressive brain tumor, by using a modified herpes virus along with a method to block a signaling pathway that helps the tumor resist current treatments, and it's designed to see if this combination can improve outcomes while keeping your memory and brain function safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10927417 on NIH RePORTER |
What this research studies
This research aims to create a new treatment approach for glioblastoma, a type of aggressive brain tumor, by combining a modified herpes virus with a strategy to block NOTCH signaling. NOTCH signaling is known to contribute to the tumor's resistance to existing therapies like chemotherapy and radiation. The researchers will investigate how this combination can be safely delivered to the brain and whether it can improve treatment outcomes without causing neurological side effects. They will also assess the impact of this treatment on memory and brain function, ensuring that it does not harm these critical areas.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to standard treatments.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While the approach of combining virotherapy with NOTCH blocking is innovative, similar strategies in cancer treatment have shown promise in other contexts, suggesting potential for success.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Kaur, Balveen — Augusta University
- Study coordinator: Kaur, Balveen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.